Sub-acute toxicity profile of a modified resveratrol supplement

Food and Chemical Toxicology

Volumn 59, Issue , 2013, Pages 492-500

  Sangeetha, M K ^a   Eazhisai Vallabi, D ^a   Sali, Veeresh Kumar ^a   Thanka, J ^b   Vasanthi, Hannah R ^a  

^a PONDICHERRY UNIVERSITY   (India)

^b SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

Clinical biochemistry; Hematology; Longevinex; Resveratrol; Sprague Dawley rats; Sub acute toxicity

Indexed keywords

LONGEVINEX; RESVERATROL; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG FORMULATION; DRUG SAFETY; ENZYME BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; MALE; NONHUMAN; RAT; TOXICITY TESTING; TREATMENT DURATION;

Γ-GLUTAMYLTRANSFERASE; ACID PHOSPHATASE; ACP; ALKALINE PHOSPHATASE; ALP; CLINICAL BIOCHEMISTRY; DIMETHYLSULFOXIDE; DMSO; EDTA; ETHYLENEDIAMINETETRAACETIC ACID; GGT; H&E; HEMATOLOGY; HEMATOXYLIN AND EOSIN; HEMOGLOBIN; HGB; LACTATE DEHYDROGENASE; LDH; LONGEVINEX; NO OBSERVED ADVERSE EFFECT LEVEL; NOAEL; RESVERATROL; SD; SEM; SERUM GLUTAMIC OXALOACETIC TRANSAMINASE; SERUM GLUTAMIC PYRUVIC TRANSAMINASE; SGOT; SGPT; SPRAGUE DAWLEY RATS; STANDARD ERROR MEANS; SUB-ACUTE TOXICITY; ULN; UPPER LIMIT OF NORMAL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIOXIDANTS; CARDIOTONIC AGENTS; COUMARIC ACIDS; DIETARY SUPPLEMENTS; FEMALE; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHYTIC ACID; QUERCETIN; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; TOXICITY TESTS, SUBACUTE;

EID: 84880625021     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.06.037     Document Type: Article

References (40)

1. American Biogenics Corp. (ABC), 1988. 2,3,4,6-Tetrachlorophenol: 90-Day subchronic oral toxicity study in rats. Sponsored by US EPA, Office of Solid Waste. Study No. 410-2522.
2. Andrade R.J., Carmen López-Vega M., Isabel Lucena M. Drug-induced hepatotoxicity. Hepatol. Rev. 2007, 4:14-23.
3. Barger J.L., Kayo T., Pugh T.D., Prolla T.A., Weindruch R. Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Exp. Gerontol. 2008, 43:859-866.
4. Boocock D.J., Faust G.E., Patel K.R., et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 2007, 16(6):1246-1252.
5. Bråkenhielm E., Cao R., Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001, 15(8):U568-U581.
6. Carbó N., Costelli P., Baccino F.M., Ló pez-Soriano F.J., Argilés J.M. Resveratrol, a natural product present in wine, decreases tumor growth in a rat tumor model. Biochem. Biophys. Res. Commun. 1999, 254:739-743.
7. Choi H., Kim J., Kim J., Joo H., Kang Y. Hypoglycemic effect of quercetin in animal models of diabetes. FASEB J. 2010, 24:722.
8. Condie L.W., Bernard D.F., Olson G.R., Robinson M. Ten and ninety-day toxicity studies of chloropicrin in sprague-dawley rats. Drug Chem. Toxicol. 1994, 17(2):125-137.
9. Cottart C.H., Nivet-Antoine V., Laguillier-Morizot C., Beaudeux J.L. Resveratrol bioavailability and toxicity in humans. MolNutr Food Res. 2010, 54(1):7-16.
10. Damsch S., Eichenbaum G., Tonelli A., Lammens L., Van den Bulck K., Feyen B., Vandenberghe J., Megens A., Knight E., Kelley M. Gavage-related reflux in rats: identification, pathogenesis, and toxicological implications. Toxicol. Pathol. 2011, 39(2):348-360.
11. Das S., Das D.K. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat Cardiovasc Drug Discov 2007, 2:133-138.
12. Espín J.C., García-Conesa M.T., Tomás-Barberán F.A. Nutraceuticals: facts and fiction. Phytochemistry 2007, 68(22-24):2986-3008.
13. Fujitaka K., Otani H., Jo F., Jo H., Nomura E., Iwasaki M., Nishikawa M., Iwasaka T., Das D.K. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr. Res. 2011, 31:842-847.
14. Gayathri V., Muthulakshmi V., Chandronitha C., Vasanthkumar M., Ramakrishnan G., Ananthi S., Kuruvilla S., Vasanthi H.R. Toxicological evaluation of an antilithiatic polyherbal Siddha formulation - SirupeellaiSamoolaKudineer in experimental rats. Human Exp. Toxicol. 2010, 30(8):952-964.
15. Gusman J., Malonne H., Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001, 22(8):1111-1117.
16. Howard, D. 2000. The biological effects of resveratrol, a red wine constituent. Nutrition Bytes. <>. http://www.medsch.ucla.edu/som/ddo/biolchem/nut-1998/Bits9798/b00howard.htm.
17. Johannsen F.R., Levinskas G.J. Comparative chronic toxicity and carcinogenicity of acrylonitrile by drinking water and oral intubation to Spartan® Sprague-Dawley rats. Toxicol. Lett. 2002, 132(3):197-219.
18. Juan M.E., Vinardell M.P., Planas J.M. The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J. Nutr. 2002, 132(2):257-260.
19. Juhasz B., Mukherjee S., Das D.K. Hormetic response of resveratrol against cardioprotection. ExpClinCardiol. 2010, 15(4):e134-138.
20. Juhaz B., Das D.K., Kertesz A., Juhasz A., Gesztelyi R., Varga B. Reduction of blood cholesterol and ischemic injury in the hypercholesteromic rabbits with modified resveratrol, logevinex. Mol. Cell Biochem. 2011, 348:199-203.
21. Jung E.H., Kim S.R., Hwang I.K., Ha T.Y. Hypoglycemic effects of a phenolic acid fraction of rice bran and ferulic acid in C57BL/KsJ-db/db Mice. J. Agric. Food Chem. 2007, 55(24):9800-9804.
22. Kalantari H., Das D.K. Physiological effects of resveratrol. BioFactors 2010, 36(5):401-406.
23. Marques F.Z., Markus M.A., Morris B.J. Resveratrol: cellular actions of a potent natural chemical that confers a diversity of health benefits. Int. J. Biochem. Cell Biol. 2009, 41:2125-2128.
24. Maulik N., Das D.K. Resveratrol in cardioprotection. A therapeutic promise of alternative medicine. Mol. Interv. 2006, 6:36-47.
25. Max S.R., Silbergeld E.K. Skeletal muscle glucocorticoid receptor and glutamine synthetase activity in the wasting syndrome in rats treated with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol. Appl. Pharmacol. 1987, 87:523-527.
26. Mukherjee S., Ray D., Lekli I., Bak I., Tosaki A., Das D.K. Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. Can. J. Physiol. Pharmacol. 2010, 88:1017-1025.
27. Muthulakshmi V., Gayathri V., Ananthi S., Lakshmi Sundaram R., Parameswari R.P., Thanka J., Vasanthi H.R. Safety and bioactivity potential of a traditional polyherbal formulation "SirupeelaisamoolaKudineer". J. Pharmacy Res. 2010, 3(9):2211-2214.
28. Nicoletti M. Nutraceuticals and botanicals: overview and perspectives. Int. J. Food Sci. Nutr. 2012, 63(1):2-6.
29. Nussey G., Van Vuren J.H.J., du Preez H.H. Effect of copper on the haematology and osmoregulation of the Mozambique tilápia, Oreochromismossambicus (Cichlidade). Comp. Biochem. Physiol. 1995, 111C(3):369-380.
30. Ohnishi M., Matuo T., Tsuno T., Hosoda A., Nomura E., Taniguchi H., Sasaki H., Morishita H. Antioxidant activity and hypoglycemic effect of ferulic acid in STZ-induced diabetic mice and KK-Ay mice. Biofactors 2004, 21(1-4):315-319.
31. Peterson R.E., Seefeld M.D., Christian B.J. The wasting syndrome in 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity: basic features and their interpretation. Banbury Report: Biological Mechanisms of Dioxin Action 1984, vol. 18:291-308. Cold Spring Harbor Laboratory, Plainview, NY.
32. Pieme C.A., Penlap V.N., Nkegoum B., Taziebou C.L., Tekwu E.M., Etoa F.X., Ngongang J. Evaluation of acute and subacute toxicities of aqueous ethanolic extract of leaves of Sennaalata(L.) Roxb (Ceasalpiniaceae). Afr. J. Biotechnol. 2006, 5(3):283-289.
33. Rhiouani H., El-Hilaly J., Israili H.Z., Lyoussi B. Acute and sub-chronic toxicity of an aqueous extract of the leaves of Herniariaglabra in rodents. J. Ethopharmacol. 2008, 118:378-386.
34. Richer, et al. Nutrients 2013, 5:1989-2005.
35. Rimbaud S., Ruiz M., Piquereau J., Mateo P., Fortin D. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS ONE 2011, 6(10):e26391.
36. Shashi K.R. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. Food Chem. Toxicol. 2007, 45:1551-1557.
37. Szkudelska K., Szkudelski T. Resveratrol, obesity and diabetes. Eur. J. Pharmacol. 2010, 635:1-8.
38. Turner R.T., Evans G.L., Zhang M., Maran A., Sibonga J.D. Is resveratrol an estrogen agonist in growing rats?. Endocrinology 1999, 140:50-54.
39. Vessal M., Hemmati M., Vasei M. Antidiabetic effects of quercetin in streptozocin-induced diabetic rats. Comp. Biochem. Physiol. 2003, 135:357-364.
40. WHO/IPCS (World Health Organization/International Programme on Chemical Safety), 1989. Polychlorinated dibenzo-p-dioxins and dibenzofurans. Environmental Health Criteria 88.